Statement of Ownership (sc 13g)
February 13 2020 - 1:46PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
SCHEDULE 13G
Under the Securities Exchange Act of
1934
(Amendment No. __)*
_____________________
NeuroBo
Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
64132R
107
(CUSIP Number)
December 30, 2019
(Date of Event Which Requires Filling of This Statement)
____________________
Check the appropriate
box to designate the rule pursuant to which this Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 64132R 107
|
(1)
|
Names of reporting persons:
Roy Lester Freeman
|
(2)
|
Check the appropriate box if a member of
a group (see instructions):
(a) [_] (b)
[X]
|
(3)
|
SEC use only
|
(4)
|
Citizenship or place of organization:
United States
|
Number of shares beneficially owned by each reporting person with:
|
(5)
|
Sole voting power:
1,456,160
|
(6)
|
Shared voting power:
0
|
(7)
|
Sole dispositive power:
1,456,160
|
(8)
|
Shared dispositive power:
0
|
(9)
|
Aggregate amount beneficially owned by
each reporting person:
1,456,160
|
(10)
|
Check if the aggregate amount in row (9)
excludes certain shares (see instructions):
[_]
|
(11)
|
Percent of class represented by amount
in row (9):
9.3% (Based on 15,592,718 shares issued
and outstanding as of December 30, 2019)
|
(12)
|
Type of reporting person (see instructions):
IN
|
|
|
|
|
Item 1(a) Name of issuer.
NeuroBo Pharmaceuticals, Inc.
Item 1(b) Address of issuer’s
principal executive offices.
200 Berkeley Street, Office 19W115
Boston, Massachusetts 02116
Item 2(a) Name of person filing.
Roy Lester Freeman
Item 2(b) Address or principal business
office or, if none, residence.
The principal business office of the reporting
person is:
200 Berkeley Street, Office 19W115
Boston, Massachusetts 02116
Item 2(c) Citizenship.
Dr. Freeman is a United States citizen.
Item 2(d) Title of class of securities.
Common Stock
Item 2(e) CUSIP Number.
64132R 107
Item 3. If this statement is filed
pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable
Item 4. Ownership.
As of December 30, 2019, the reporting
person beneficially owns 1,456,160 shares of the issuer’s Common Stock, representing 9.3% of the class of securities based
on 15,592,718 shares issued and outstanding as of December 30, 2019.
Number of shares as to which the reporting
person has:
(i) Sole power to
vote or to direct the vote: 1,456,160
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to
dispose or to direct the disposition of: 1,456,160
(iv) Shared power to
dispose or to direct the disposition of: 0
Item 5. Ownership of 5 Percent or
Less of a Class.
Not applicable
Item 6. Ownership of More than 5 Percent
on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable
Item 8. Identification and Classification
of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
Item 10. Certifications.
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with
the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination
under § 240.14a-11.
Signature. After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2020
|
/s/ Roy Lester Freeman
|
|
Roy Lester Freeman
|
|
|
|
|
|
|
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Sep 2023 to Sep 2024